Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. - Wikidata - wikimedia - TriplyDB

Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

http://www.wikidata.org/entity/Q35704462

about

Diabetic macular edema: it is more than just VEGF Updates on the Clinical Trials in Diabetic Macular Edema Novel pharmacotherapies in diabetic retinopathy: Current status and what's in the horizon?Diabetic macular oedema: evidence-based treatment recommendations for Asian countries.Retinal microvascular alterations related to diabetes assessed by optical coherence tomography angiography: A cross-sectional analysis.Fundamental principles of an anti-VEGF treatment regimen: optimal application of intravitreal anti-vascular endothelial growth factor therapy of macular diseases A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy.Treatment strategies for refractory diabetic macular edema: switching anti-VEGF treatments, adopting corticosteroid-based treatments, and combination therapy.Recent advancements in diabetic retinopathy treatment from the Diabetic Retinopathy Clinical Research Network Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.Combination of vascular endothelial growth factor inhibitors and laser therapy for diabetic macular oedema: a review.Current and investigational drugs for the treatment of diabetic retinopathy.Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.Placental growth factor and its potential role in diabetic retinopathy and other ocular neovascular diseases.Evidence-Based Treatment of Diabetic Macular Edema.Anti-VEGF treatment of diabetic macular edema in clinical practice: effectiveness and patterns of use (ECHO Study Report 1).Combination of Navigated Macular Laser Photocoagulation and Anti-VEGF Therapy: Precise Treatment for Macular Edema under Dry Retinal Conditions.Combination of Anti-VEGF and Laser Photocoagulation for Diabetic Macular Edema: A Review.Identification of time point to best define 'sub-optimal response' following intravitreal ranibizumab therapy for diabetic macular edema based on real-life data.Overview of Ocular Anti-Vascular Endothelial Growth Factor Therapy in the Management of Diabetic Eye Complications.Understanding lymphangiogenesis in knockout models, the cornea, and ocular diseases for the development of therapeutic interventions.Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.Predicting outcomes to anti-vascular endothelial growth factor (VEGF) therapy in diabetic macular oedema: a review of the literature.Aflibercept in diabetic macular edema: evaluating efficacy as a primary and secondary therapeutic option.A Review: Proteomics in Retinal Artery Occlusion, Retinal Vein Occlusion, Diabetic Retinopathy and Acquired Macular Disorders.Update on Diagnosis and Treatment of Diabetic Retinopathy: A Consensus Guideline of the Working Group of Ocular Health (Spanish Society of Diabetes and Spanish Vitreous and Retina Society).Comparisons of Efficacy of Intravitreal Aflibercept and Ranibizumab in Eyes with Diabetic Macular Edema.Protective effects on the retina after ranibizumab treatment in an ischemia model Dexamethasone Intravitreal Implant in Diabetic Macular Edema: Real-Life Data from a Prospective Study and Predictive Factors for Visual Outcome.Outcomes of Intravitreal Dexamethasone Implant in the Treatment of Recalcitrant Diabetic Macular Edema.Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study.Recent advances in the management and understanding of diabetic retinopathy.Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.Impact of baseline Diabetic Retinopathy Severity Scale scores on visual outcomes in the VIVID-DME and VISTA-DME studies.Efficacy of One-Year Treatment with Aflibercept for Diabetic Macular Edema with Practical Protocol.Switching to Aflibercept in Diabetic Macular Edema Not Responding to Ranibizumab and/or Intravitreal Dexamethasone Implant.Management of diabetic macular edema in Japan: a review and expert opinion.Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice.Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab.Aflibercept in the treatment of diabetic macular edema: a review and consensus paper.

P2860

Q26745914-CD6A5A06-AB9D-4744-A47A-B52D7B3D1363 Q26767100-82ED2EEE-EE0E-42C3-8BC1-2287BDBA234D Q28066675-2ECC97AC-EC6E-426F-ACCB-CFEECB8240C6 Q30101045-9369E3C5-2224-47A0-8D8C-1E0780D9D169 Q33597198-9DEF0940-C623-4240-B95F-35503D6A80AF Q33840787-23D17705-DBA4-42A9-996B-EEFF10183001 Q34510550-F085E912-E75A-4742-B362-17A07CEB7FF3 Q35870506-B8711D5B-6598-4F72-99F9-991835DC27DD Q35935370-67EB8D3D-CDD8-4F92-83B7-4350D0840DDE Q35943499-8C60A684-70C3-42B4-9726-68386515079D Q35984696-1F782B41-402C-4B4C-BD12-64D2E7CFF54D Q36066049-06D8CEDA-1755-42A6-A548-7AC7DBC79611 Q36161138-D8AD3EC7-60EB-4D84-B7FC-8B63E036A52B Q36200924-8E670D59-B773-42B5-A1A7-56F394F12E9F Q36242390-B393B5AE-14F6-4A14-A711-DCB4BBABB861 Q36297613-44903785-D2E8-4175-BB87-F1E1690AB898 Q36313966-DC413625-9D16-46A5-A776-6D4EF583ECA2 Q36324841-064A813C-3BA4-48F6-B5E5-858F4E61A15F Q36407311-930FBB01-575D-4C3C-BA5C-7016759583F1 Q36585191-54003D59-1247-4A42-8295-94F04D540784 Q36808641-2EF5AD6D-9111-47D5-B26E-CD50978044B6 Q38817006-121E9063-46A7-4908-A0C1-4071DBAB55C8 Q38845769-3644048E-8D83-4EFB-9D60-E2CCBE557EA5 Q38937864-44A9083B-FDD0-483B-AB6F-9805A53C3458 Q39269575-69D5B45C-0AC6-407D-B312-CC0C39DD620C Q39427264-D9D76B49-2E6D-485A-A64F-F49801BF1503 Q41025677-561877A4-5C35-41BE-9295-89B34DB3BFA8 Q41363983-A3D9F5D0-892D-4ABB-AC93-97265ACFC4FC Q46249426-C120ADFD-3924-4D99-A4F7-BFA158143AB6 Q47095285-78F638E0-643A-4A09-89E4-1AA1EFA684C4 Q47166322-085357A3-34C2-47F2-9F36-984465A8C79B Q47168388-EA6F9A26-17F8-476B-BEB7-CE9078387903 Q47310979-617F137B-38EA-4E05-ADA6-8AA1BDBD5A26 Q47428173-4CE01E9B-7E01-45AD-A26C-98166823D35C Q48213638-C5FF5B43-892E-4095-BBF0-CE6C9B9D5936 Q48357856-432C2C0D-A720-483D-81F0-6B41C4354898 Q48579709-077D7FA8-8884-4A1A-A0DE-3DD935BB89F5 Q49275652-AA0DA08F-284F-4A18-9AF1-27DF3011985E Q49882109-526CB222-E7B4-4C8B-BB27-146F2FA9DF85 Q50095639-49359551-082E-42A4-BB4B-51AB91F6E51E

P2860

Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies.

http://www.wikidata.org/entity/Q35704462

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.

@ast

Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.

@en

type

label

Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.

@ast

Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.

@en

prefLabel

Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.

@ast

Intravitreal Aflibercept for D ...... m the VISTA and VIVID Studies.

@en

P1433

Q35704462-A1687635-A4DE-4212-8F60-1B22E9E52BDF

P1476

Q35704462-78893D71-12E6-4A5D-871E-91CA4C95977B

P2093

Q35704462-0F430741-86CB-4185-9353-1E76BD500324

Q35704462-15C16C0C-1539-4285-B5DA-8971649CF906

Q35704462-1C1200DF-34B9-4E9B-8523-B6F466EBCE6F

Q35704462-2622380C-E99E-4B7B-9DBC-2C7646186310

Q35704462-37E6A06C-1E76-4D71-AC4D-A29B545A341E

Q35704462-39B94717-EE08-4E0F-B5EF-857055783A2C

Q35704462-3BEB01A3-4DD3-45E6-AC4B-5817D82EC8F2

Q35704462-507B432B-1E7B-4BD1-81AC-5C1BDAF2C4FD

Q35704462-5E85BBCB-B7D1-4FF9-B976-0BBC5873867D

Q35704462-7B29978D-EBA4-4422-B881-FC66929B8E87

P304

Q35704462-B226B4AB-7841-40E1-9849-E2CCC2E61FFD

P31

Q35704462-ED50B194-054A-4686-B7C6-2824759DE2FC

P356

Q35704462-D3B8C70C-48F3-4D05-A965-567AC95308E2

P433

Q35704462-E91D0E89-2EAA-4710-B9F2-6F1542102E86

P478

Q35704462-4099EC6D-1E73-4DE9-9ED7-C005906573FB

P50

Q35704462-74240371-1819-49EE-9E48-878CB5BAF6C0

Q35704462-8ECB3C5F-D4F1-4D4A-ABEF-42A502891B9C

P577

Q35704462-02D35763-56BD-4423-947B-8BB55358E112

P698

Q35704462-BE2D7B07-3249-4F56-9546-28B552656C5F

P356

J.OPHTHA.2015.06.017

P1433

P1476

Intravitreal Aflibercept for D ...... om the VISTA and VIVID Studies

@en

P2093

Alyson J Berliner

http://www.w3.org/2001/XMLSchema#string

Carola Metzig

http://www.w3.org/2001/XMLSchema#string

Christian Simader

http://www.w3.org/2001/XMLSchema#string

David M Brown

http://www.w3.org/2001/XMLSchema#string

David S Boyer

http://www.w3.org/2001/XMLSchema#string

Dennis M Marcus

http://www.w3.org/2001/XMLSchema#string

Diana V Do

http://www.w3.org/2001/XMLSchema#string

Edoardo Midena

http://www.w3.org/2001/XMLSchema#string

Frank G Holz

http://www.w3.org/2001/XMLSchema#string

George D Yancopoulos

http://www.w3.org/2001/XMLSchema#string

P304

2044-2052

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2015.06.017

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P50

Ursula Schmidt-Erfurth

P577

2015-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26198808

http://www.w3.org/2001/XMLSchema#string